See more : Surmodics, Inc. (SRDX) Income Statement Analysis – Financial Results
Complete financial analysis of Kuros Biosciences AG (0RHR.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kuros Biosciences AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Lion Travel Service Co., Ltd. (2731.TW) Income Statement Analysis – Financial Results
- Dolly Varden Silver Corporation (0USB.L) Income Statement Analysis – Financial Results
- Beard Energy Transition Acquisition Corp. (BRD-UN) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMAG) Income Statement Analysis – Financial Results
- Ryohin Keikaku Co., Ltd. (7453.T) Income Statement Analysis – Financial Results
Kuros Biosciences AG (0RHR.L)
About Kuros Biosciences AG
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.56M | 17.99M | 13.82M | 4.04M | 2.56M | 715.00K | 534.00K | 1.06M | 6.36M | 1.00M | 1.00M | 1.10M | 1.57M | 22.35M | 9.11M | 19.72M | 35.88M | 724.00K | 4.36M | 4.11M |
| Cost of Revenue | 9.63M | 7.22M | 3.75M | 2.37M | 2.64M | 3.42M | 3.31M | 7.91M | 563.00K | 10.10M | 12.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.40M | 11.20M | 0.00 | 0.00 |
| Gross Profit | 23.94M | 10.77M | 10.07M | 1.67M | -79.00K | -2.70M | -2.77M | -6.85M | 5.79M | -9.10M | -11.95M | 1.10M | 1.57M | 22.35M | 9.11M | 19.72M | 18.48M | -10.48M | 4.36M | 4.11M |
| Gross Profit Ratio | 71.31% | 59.87% | 72.86% | 41.37% | -3.08% | -377.76% | -518.91% | -645.43% | 91.14% | -910.10% | -1,194.90% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 51.51% | -1,446.96% | 100.00% | 100.00% |
| Research & Development | 5.60M | 5.19M | 4.99M | 4.01M | 6.48M | 6.88M | 4.47M | 7.91M | 1.09M | 17.47M | 20.45M | 10.89M | 16.69M | 22.21M | 32.97M | 39.50M | 0.00 | 0.00 | 29.48M | 26.14M |
| General & Administrative | 3.56M | 3.07M | 2.58M | 3.14M | 1.54M | 2.77M | 1.82M | 17.07M | 7.32M | 5.28M | 5.40M | 4.98M | 5.48M | 4.09M | 3.00M | 3.67M | 1.41M | 1.46M | 3.78M | 3.62M |
| Selling & Marketing | 17.13M | 8.08M | 4.80M | 1.56M | 2.30M | 348.00K | 0.00 | 0.00 | 46.00K | 202.00K | 473.00K | 330.00K | 471.00K | 738.00K | 858.00K | 958.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.09M | 11.15M | 7.38M | 4.70M | 1.54M | 2.77M | 1.82M | 17.07M | 7.37M | 5.48M | 5.88M | 5.31M | 5.95M | 4.82M | 3.86M | 4.63M | 1.41M | 1.46M | 3.78M | 3.62M |
| Other Expenses | 0.00 | 7.87M | 6.46M | 4.65M | 9.77M | 8.25M | 9.45M | -2.60M | -2.75M | -3.01M | -2.06M | -1.60M | -1.35M | -824.00K | -481.00K | -512.00K | -12.00K | 2.00K | 419.00K | -1.47M |
| Operating Expenses | 37.13M | 24.22M | 18.83M | 13.35M | 11.31M | 11.03M | 11.28M | 22.41M | 5.14M | 9.84M | 24.27M | 14.60M | 21.29M | 26.21M | 36.35M | 43.61M | 27.81M | 25.04M | 33.68M | 28.29M |
| Cost & Expenses | 46.91M | 31.43M | 22.58M | 15.72M | 13.95M | 14.44M | 14.58M | 22.41M | 5.70M | 19.94M | 24.27M | 14.60M | 21.29M | 26.21M | 36.35M | 43.61M | 45.21M | 36.24M | 33.68M | 28.29M |
| Interest Income | 400.00K | 1.77M | 596.00K | 433.00K | 220.00K | 40.00K | 43.00K | 1.21M | 11.23M | 88.00K | 260.00K | 7.16M | 3.92M | 6.57M | 6.92M | 2.38M | 2.17M | 592.00K | 994.00K | 412.00K |
| Interest Expense | 186.00K | 4.32M | 1.38M | 848.00K | 651.00K | 126.00K | 393.00K | 145.00K | 5.66M | 15.19M | 7.83M | 3.82M | 2.99M | 4.17M | 4.52M | 4.51M | 3.74M | 52.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.75M | 2.83M | 2.88M | 2.67M | 2.71M | 1.95M | 1.15M | 820.00K | 11.23M | 9.00K | 85.00K | 75.00K | 1.73M | 2.05M | 2.48M | 2.74M | 2.85M | 2.79M | 2.57M | 2.42M |
| EBITDA | -10.41M | -8.84M | -5.29M | -8.58M | -8.46M | -11.74M | -15.10M | -19.31M | -4.06M | -18.84M | -22.92M | -6.30M | -14.06M | 4.77M | -17.84M | -18.76M | -3.27M | -31.71M | -26.75M | -21.76M |
| EBITDA Ratio | -31.01% | -49.15% | -38.30% | -212.35% | -330.26% | -1,641.96% | -2,407.49% | -1,820.17% | 187.00% | -1,872.80% | -2,291.60% | -568.55% | -894.84% | 21.33% | -195.82% | -95.12% | -22.40% | -4,445.17% | -613.81% | -529.06% |
| Operating Income | -13.19M | -13.45M | -8.77M | -11.68M | -11.39M | -13.73M | -16.24M | -21.35M | 654.00K | -18.94M | -23.27M | -13.50M | -19.71M | -3.86M | -27.24M | -23.88M | -8.30M | -35.09M | -29.32M | -24.18M |
| Operating Income Ratio | -39.30% | -74.76% | -63.46% | -289.16% | -444.83% | -1,919.86% | -3,041.76% | -2,011.88% | 10.29% | -1,893.70% | -2,326.60% | -1,226.82% | -1,254.87% | -17.29% | -299.07% | -121.09% | -23.13% | -4,846.82% | -672.72% | -587.94% |
| Total Other Income/Expenses | -155.00K | -2.55M | -787.00K | -415.00K | -431.00K | -86.00K | -350.00K | 1.07M | -1.61M | -15.09M | -7.56M | 3.34M | 935.00K | 2.41M | 2.41M | -2.13M | -1.57M | 539.00K | 837.00K | 326.00K |
| Income Before Tax | -13.35M | -15.99M | -9.55M | -12.09M | -11.82M | -13.81M | -16.59M | -20.28M | 6.23M | -34.03M | -30.83M | -10.15M | -18.78M | -1.45M | -24.83M | -26.01M | -9.87M | -34.55M | 0.00 | 0.00 |
| Income Before Tax Ratio | -39.77% | -88.91% | -69.16% | -299.43% | -461.66% | -1,931.89% | -3,107.30% | -1,911.12% | 97.99% | -3,402.60% | -3,082.60% | -922.55% | -1,195.35% | -6.51% | -272.57% | -131.87% | -27.50% | -4,772.38% | 0.00% | 0.00% |
| Income Tax Expense | 380.00K | -1.40M | -2.01M | -574.00K | -571.00K | -2.12M | -109.00K | -533.00K | -46.00K | 200.00K | 265.00K | -932.00K | 3.93M | 6.58M | 6.93M | 2.39M | -2.99M | 539.00K | -837.00K | -326.00K |
| Net Income | -13.73M | -14.60M | -7.54M | -11.52M | -11.25M | -11.69M | -16.48M | -19.74M | 6.23M | -34.03M | -30.83M | -9.22M | -18.78M | -1.45M | -24.83M | -26.01M | -6.88M | -34.55M | -28.48M | -23.85M |
| Net Income Ratio | -40.90% | -81.15% | -54.59% | -285.22% | -439.36% | -1,635.38% | -3,086.89% | -1,860.89% | 97.99% | -3,402.60% | -3,082.60% | -837.82% | -1,195.35% | -6.51% | -272.57% | -131.87% | -19.16% | -4,772.38% | -653.51% | -580.01% |
| EPS | -0.38 | -0.43 | -0.23 | -0.47 | -0.66 | -1.14 | -1.88 | -3.19 | -226.97 | -96.70 | -106.63 | -45.88 | -287.82 | -22.29 | -380.59 | -399.02 | -106.15 | -542.49 | -461.63 | -435.51 |
| EPS Diluted | -0.38 | -0.43 | -0.23 | -0.47 | -0.66 | -1.14 | -1.88 | -3.19 | -226.97 | -96.70 | -106.63 | -45.88 | -287.82 | -22.29 | -380.59 | -399.02 | -106.15 | -542.49 | -461.63 | -435.51 |
| Weighted Avg Shares Out | 36.58M | 33.90M | 32.79M | 24.32M | 17.17M | 10.24M | 8.78M | 6.20M | 25.49K | 351.86K | 289.09K | 200.88K | 65.25K | 65.24K | 65.23K | 65.18K | 64.77K | 63.69K | 61.69K | 54.76K |
| Weighted Avg Shares Out (Dil) | 36.58M | 33.90M | 32.79M | 24.32M | 17.17M | 10.24M | 8.78M | 6.20M | 25.49K | 351.86K | 289.09K | 200.88K | 65.25K | 65.24K | 65.23K | 65.18K | 64.77K | 63.69K | 61.69K | 54.76K |
Source: https://incomestatements.info
Category: Stock Reports